Atherosclerosis is a pathological process that takes place in the major arteries and is the underlying cause of heart attacks, stroke and peripheral artery disease. The earliest detectable lesions, called fatty streaks , 
macrophage-derived foam cells that differentiate from recruited blood monocytes. Monocytes are recruited to tissues via constitutive signals and in response to inflammatory mediators. Monocyte recruitment and macrophage differentiation are also a central feature of other important human diseases characterised by chronic inflammation such as rheumatoid arthritis and tuberculosis (Refs 3, 4).
expert reviews in molecular medicine
More-advanced atherosclerotic lesions, called fibro-fatty plaques, are the result of continued monocyte recruitment, together with smooth muscle cell migration and proliferation (Ref. 5) , and can contain CD4 + T cells (Ref. 6 ). Chemokines or chemoattractant cytokines constitute a family of over 40 different cellsignalling molecules important for constitutive trafficking and recruitment of leukocytes in response to inflammatory mediators ( Refs 7, 8, 9, 10) . Some chemokines that can act as potent mediators of monocyte migration and macrophage differentiation are expressed in human atherosclerotic lesions (Ref. 11) . Indeed, as discussed below, experiments performed with gene-knockout mice lacking macrophage chemoattractant protein 1 (MCP-1) have suggested an important role for the CC chemokine MCP-1 and its specific receptor CCR2 in the initial stages of atherogenesis (Ref. 12) .
In recent years, pathologists have advanced the idea of stable and unstable (or vulnerable) atherosclerotic plaques (Ref. 13) . Stable plaques are characterised by a thick fibrous cap overlying a plaque that does not contain a cholesterol-rich necrotic core. By contrast, unstable plaques have a thin fibrous cap, contain a higher ratio of macrophages to smooth muscle cells, and have a lipid-filled necrotic core (Ref. 14) . Unstable plaques are more likely to rupture, which exposes the thrombogenic core of the lesion to arterial blood. This leads to platelet aggregation and the formation of an arterial thrombus attached to the vessel wall. Thrombus material can break away from the wall and be transported to a distant site (embolism), where it may lead to blockage of smaller arteries. The clinical consequences of arterial thrombosis are heart attacks, strokes and renal disease. Indeed, the majority (~60%) of arterial thrombosis is associated with ruptured atherosclerotic plaques. Another commonly observed feature of atherosclerotic plaques is endothelial cell denudation (plaque erosion) and other changes in the endothelial cells that predispose to arterial thrombosis and its clinical sequelae (Ref. 15) .
This article will briefly review some key features of macrophage biology and the factors that influence the growth and development of atherosclerotic lesions (atherogenesis). The potential role of chemokines in mediating monocyte recruitment and macrophage differentiation within atherosclerotic lesions will then considered.
Macrophage biology
Macrophages are bone-marrow-derived phagocytic cells that are important for tissue homeostasis and are found in virtually all tissues of the body. Macrophages also play important roles in the innate and acquired immune responses (Ref. 16 Macrophages are responsible for tissue remodelling during development and wound repair. They secrete many different cytokines, growth factors and proteases that facilitate the remodelling of the extracellular matrix and encourage the recruitment of other cell types such as fibroblasts and smooth muscle cells that are important for wound repair. Key cytokines secreted by macrophages include interleukin 1β (IL-1β), tumour necrosis factor α (TNF-α), IL-10, IL-12 and transforming growth factor β (TGF-β). Macrophage-derived growth factors that have significant effects on the pathology of atherosclerosis include fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), which is a potent mediator of smooth muscle cell growth, migration and differentiation, and macrophage colony-stimulating factor (M-CSF), which is an autocrine mediator of macrophage differentiation.
Macrophages can also secrete numerous proteases, protease activators and protease inhibitors in response to physiological signals. Of particular interest in atherosclerosis are members of the matrix metalloproteinase (MMP) family of zinc-containing endopeptidases (Ref. 21 ). Histochemical and genetic association studies have implicated MMP-1, MMP-2, MMP-3 and MMP-9 as important players in vascular pathology (Refs 22, 23, 24, 25) . In addition, activated macrophages secrete tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA); these plasminogen activators activate the serine protease plasmin, which plays a key role in fibrinolysis (the dissolution of blood clots) (Ref. 26 ).
LDLs and macrophage scavenger receptors
Scavenger receptors are defined by their ability to endocytose modified (e.g. acetylated or oxidised) forms of LDL and were first described by Goldstein and Brown in 1979 (Ref. 27) . LDL consists of a cholesterol-rich core packaged by phospholipids and a specific set of apolipoproteins, such as apoB 100 , that target uptake via the LDL receptor (LDLR). LDLs transport cholesterol and triglycerides from the liver to extrahepatic tissues and are taken up and catabolised by specific receptor-mediated endocytosis. Both the lipid and protein moieties of LDL are subject to oxidative damage through the action of free radicals. There is some debate about the precise nature of the chemical modifications to LDL in vivo but it is clear that oxidised LDL is highly atherogenic (Ref. 28) . Unlike the classical LDLR, which is downregulated by increasing cellular cholesterol levels, the ability of scavenger receptors to take up modified LDL is not inhibited by increasing cellular cholesterol. This leads to the appearance of macrophagederived foam cells whose cytoplasm is swollen with lipid droplets. Lipid-laden foam cells are found within the sub-endothelial space of the arteries in fatty streak lesions, which are the first recognisable atherosclerotic lesions, as well as in more-advanced unstable atherosclerotic plaques (Refs 29, 30) .
Molecular cloning has identified at least eight different scavenger receptors that can be expressed by macrophages (Refs 29, 30 ). These receptors have very different structures and can bind and internalise a wide range of polyanionic ligands, including modified forms of LDL (see Table 1 ). The relative contribution of some scavenger receptors has been assessed in geneknockout mice and the macrophage scavenger receptors SR-A and CD36 are known to be important in animal models of atherogenesis. Indeed, mice with a disruption in the gene Following damage to the endothelium, monocytes are recruited into the subendothelial space, where they differentiate into macrophages. These recruited macrophages endocytose modified forms of LDL via scavenger receptors to form foam cells, the hallmark of fatty streak lesions. The lesions develop into fibro-fatty plaques, which contain large numbers of macrophages and some CD4 + T cells, and show evidence of smooth muscle migration and proliferation ( Fig. 1) . In human arteries, these fibro-fatty plaques develop into complex atherosclerotic lesions that are liable to rupture (Refs 35, 36) .
Prospective studies have identified several important risk factors for the development of coronary heart disease in human populations. These include smoking, diabetes, hypertension, elevated plasma LDL-cholesterol levels and a family history of heart disease (Ref. 37) . In order to define the precise molecular mechanisms by which these environmental and genetic factors influence the process of atherosclerosis, it is essential to study animal models of arterial disease. The most widely used small animal model of atherosclerosis is the apoE-knockout mouse developed in the laboratories of Jan Breslow and Nobuyo Maeda (Refs 38, 39).
Atherosclerosis models
The apolipoprotein apoE is the main protein ligand on the surface of the murine LDL particle, which is recognised by the LDLR. Mice that lack a functional gene encoding apoE have elevated levels of plasma LDL-cholesterol (hypercholesterolaemia). Plasma cholesterol levels can be further elevated by feeding mice a 'western-type diet' containing 21% fat and 0.2% cholesterol. Feeding apoE −/− mice such a high-fat diet results in the development of atherosclerotic lesions in their major arteries, including the aorta and coronary arteries. Although the murine apoE and LDLR geneknockout models do not recapitulate all the features of human atherosclerosis, they have been widely used to study the effect of specific genes on the earliest stages of atherogenesis. Furthermore, several intervention studies have been performed in apoE −/− and LDLR −/− mice to test the effect of drugs and blocking mAbs on atherosclerotic lesion development. Several studies have revealed an important role for macrophages and macrophage-derived products in atherosclerosis (see Table 2 ). Ablation of genes involved in various aspects of macrophage differentiation or function result in a decrease in the development of atherosclerotic lesions in these mice, indicating an active role for macrophages in the initiation and growth of atherosclerotic plaques. For an excellent review of genetic modifiers of atherosclerosis in mouse models, see Ref. 41 . The CXC (or α-) chemokines have a single amino acid separating the two amino terminal cysteine residues (C1, C2) of the protein, while CC (or β-) chemokines have no amino acid separating the signature C1 and C2 cysteines. Chemokines mediate their effects via interaction with specific chemokine receptors expressed on a wide range of cell types. The CC chemokine receptors are CCR1 to CCR9, and the CXC chemokine receptors are CXCR1 to CXCR6. The fractalkine receptor is CX 3 CR1 and the lymphotactin receptor is XCR1 (Ref. 43) . A list of the currently identified human chemokine receptors and their chemokine ligands is given in Table 3 (Refs 9, 43).
Chemokine receptors are G-protein-coupled receptors (GPCRs) with seven transmembrane (TM7) spanning α-helices. Chemokines bind to their cognate chemokine receptor with high affinity (typically with a dissociation constant of Kd ~1-3 nM). Chemokine receptors are unusual among the many characterised members of the TM7 receptor superfamily in having multiple high-affinity ligands for a single receptor. A good example of this is the CCR4 receptor, which binds the CC chemokines macrophagederived chemokine (MDC) and thymus-and activation-regulated chemokine (TARC) with high affinity and mediates cellular signalling with nanomolar concentrations of either chemokine ligand (Ref. 44) .
Binding of a chemokine to its specific receptor on the cell surface leads to the generation of an intracellular signal via a Gα I -containing G-protein complex and this results in cell chemotaxis towards the source of the chemokine. This process is inhibited by pertussis toxin. In addition to these short-lived signals, some Many important human diseases, including asthma, arthritis and atherosclerosis are characterised by acute or chronic recruitment of leukocytes from the blood into affected tissues. Chemokines have been implicated as inflammatory mediators in a wide range of pathologies on the basis of studies using clinical material and animal disease models (for reviews, see Refs 50, 51) . At first sight, the chemokine network, with its multiple highaffinity ligands and 'promiscuous' receptors, might seem like a cellular signalling system with a great deal of redundancy. However, analysis of chemokine-and chemokine-receptor-knockout mice has revealed a unique, non-redundant role for some chemokines in leukocyte trafficking, inflammation and immunity.
Chemokine-and chemokine-receptorknockout mice
Initial characterisation of chemokine-and chemokine-receptor-knockout animals has revealed that some ligand-receptor interactions play a key role in the development of the haematopoietic system. One example is the binding of stromal-cell-derived factor (SDF-1) to CXCR4; animals in which genes encoding these proteins are ablated are not viable (Refs 52, 53). Ablation of the murine CXC chemokine receptor CXCR2 causes specific defects in constitutive leukocyte trafficking, with CXCR2 gene-knockout animals exhibiting lymphadenopathy owing to increased numbers of B cells and neutrophils (Ref. 54) .
Other chemokine-knockout animals have less obvious phenotypes and exhibit no significant differences in constitutive leukocyte trafficking. Differences in inflammatory cell recruitment are only seen when the animals are immunised, challenged with specific pathogens or subjected to physiological stress. An early example of this was the specific defect in antiviral immunity seen in MIP-1α gene-knockout mice (Ref. 55) . Another example, which will be discussed in greater detail in the next section, is deletion of the gene encoding the CC chemokine MCP-1. Mice homozygous for deletion of the gene encoding MCP-1 exhibit no obvious phenotype but, when on a C57/BL6 mouse background and crossed with apoE −/− mice, a significant decrease in the size of atherosclerotic lesions is observed (Ref. 56) . This provides important evidence that MCP-1 plays a nonredundant role in monocyte recruitment and/or macrophage retention in atherosclerotic lesions. A summary of important observations made with chemokine-and chemokine-receptor-knockout animals is provided in Table 4 . The list is not exhaustive and new observations will be added as gene-knockout animals are studied more closely in a wider range of disease models.
The role of MCP-1 and CCR2 in atherogenesis
Much of the current interest in the role of chemokines in atherogenesis stems from experiments performed in MCP-1 and CCR2 gene-knockout mice. MCP-1 was among the first of the CC chemokines to be described. MCP-1 (originally called JE) was identified as a PDGFinduced transcript and shown to be a potent chemoattractant for monocytes (Ref. expert reviews in molecular medicine because of the effects of MCP-1 on monocyte chemotaxis but also because of recently described effects of MCP-1 on triggering firm adhesion of monocytes to activated endothelium. Addition of the CC chemokine MCP-1 or the CXC chemokine IL-8 can cause rapid arrest of human monocytes rolling on E-selectin-expressing endothelial cells under flow conditions (Ref. 67 ). This rapid arrest of rolling monocytes is blocked by antibodies that specifically recognise α and β integrins. These in vitro experiments suggest that MCP-1 could play a doubly important role in monocyte recruitment by mediating both monocyte chemoattraction and firm adhesion of rolling monocytes to activated endothelial cells.
Other biological effects of MCP-1 and CCR2 that might be relevant in the context of atherogenesis are beginning to emerge. One interesting defect in MCP-1-deficient mice is a polarisation of the adaptive immune system towards T helper 1 (Th1)-type immune responses, characterised by the production of interferon γ (IFN-γ) and IL-2, and low levels of expression of the Th2-type cytokines IL-4 and IL-10 (Ref. 68 ). Thus, high levels of MCP-1 expression within an atherosclerotic plaque containing CD4 + T cells could favour the elaboration of a Th2-type immune response characterised by the expression of Th2 cytokines, which might favour the elaboration of a wound repair response rather than inflammation. It is likely that the multiple effects of MCP-1 on monocyte migration, monocyte adhesion, macrophage differentiation and immune responses account for the growing number of defects observed in experimental disease models in CCR2-knockout mice (see Table 4 ).
The expression of other CC chemokines in atherosclerosis
Recent gene expression experiments using a DNA microarray of 8600 expressed genes has revealed that the expression of the CC chemokine eotaxin is markedly upregulated in aortic smooth muscle cells treated with TNF-α (Ref. 69) . Immunohistochemical a n a l y s i s of human atherosclerotic lesions showed expression of eotaxin by smooth muscle cells and the presence of CCR3 + cells within macrophagerich regions of the plaques. Interestingly, the CCR3 chemokine receptor is preferentially expressed on eosinophils, mast cells and Th2-type CD4
The genes that encode the CC chemokines MDC and TARC and the CX 3 C chemokine fractalkine are linked on human chromosome 16q13 (Ref. 71) . Expression of MDC and TARC in primary human macrophages is upregulated by the Th2 cytokines IL-4 and IL-13 but not by the Th1 cytokine IFN-γ. Furthermore, analysis of human atherosclerotic lesions by immunohistochemistry has shown that a subset of macrophages within human atherosclerotic plaques express MDC, fractalkine and TARC (Fig. 2 and Ref. 71) . It is possible that macrophage expression of these chemokines can be used as a surrogate marker of Th2-type immune responses within human atherosclerotic lesions. However, the mere presence of an inflammatory mediator in a lesion does not mean that it has a significant functional role in the pathogenesis of disease. It will be important to design experiments to critically evaluate the role of CC chemokines other than MCP-1 in atherosclerosis.
The expression of CXC chemokines in atherosclerosis
Early evidence for a potential role for CXC chemokines in atherogenesis came from experiments in which LDLR −/− mice were reconstituted with bone marrow from CXCR2-knockout mice (Ref. 72) . The size of atherosclerotic lesions was reduced in mice whose blood contained CXCR2
−/− monocytes. The chemokine receptor CXCR2 signals in response to several CXC chemokines, including IL-8 (see Table 3 
Key questions and future challenges
The aim of this review has been to illustrate the potential importance of chemokines as inflammatory mediators in atherosclerosis. There are clearly many questions concerning chemokines and atherogenesis that remain unanswered.
The dramatic effects of ablating the genes encoding MCP-1 and CCR2 in murine models of Small molecule antagonists of CCR2 have been developed and it will be interesting to see if these drugs are effective at reducing atherosclerosis in animal models of cardiovascular disease. CC chemokines other than MCP-1 are expressed in human atherosclerotic lesions and it will be important to show whether these chemokines play a non-redundant role in atherogenesis. This will require the analysis of appropriate gene-knockout animals or the use of chemokine-binding proteins such as the vCCI protein of vaccinia.
Experimental evidence for the role of CXCR2 in atherogenesis has been presented and immunohistochemistry has shown that several CXC chemokines, as well as the CX 3 C chemokine fractalkine, are expressed in human atherosclerotic plaques. Further evidence for the role of these chemokines in human atherogenesis might be provided by analysis of polymorphisms of genes encoding chemokines and chemokine receptors in human populations.
It is important to remember that chemokines are not the only class of inflammatory mediator present in atherosclerotic lesions. However, studying the expression patterns of chemokines in atherogenesis might shed light on important regulatory mechanisms (such as Th1 and Th2 immune responses) that determine the nature of the inflammatory response within the arterial wall.
Perhaps the biggest challenge faced in studying the role of chemokines in atherogenesis is identifying whether chemokine receptors offer new avenues for therapeutic intervention in human cardiovascular disease. expert reviews in molecular medicine Further reading, resources and contacts
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The following three review articles are an excellent starting point for exploring the extensive literature on macrophages, atherosclerosis and chemokines: Tables   Table 1. Macrophage scavenger receptors and their ligands (tab001dgw). Table 2 . Genes that modify macrophage biology and atherosclerosis in apoE or LDLR gene-knockout mice (tab002dgw). Table 3 . Human chemokine receptors and their ligands (tab003dgw). Table 4 . Chemokine-and chemokine-receptor-knockout mice (tab004dgw). 
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